Top

Open Access 28-09-2024 | Respiratory Microbiota | REVIEW ARTICLE

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Authors: Zhengrui Li, Jing Li, Xiaolei Bai, Xufeng Huang, Qi Wang

Published in: Clinical and Translational Oncology

Abstract

It has been spotlighted that the Tumor Microenvironment (TME) is crucial for comprehending cancer progression and therapeutic resistance. Therefore, this comprehensive review elucidates the intricate architecture of the TME, which encompasses tumor cells, immune components, support cells, and a myriad of bioactive molecules. These constituents collectively foster dynamic interactions that underpin tumor growth, metastasis, and nuanced responses to anticancer therapies. Notably, the TME’s role extends beyond mere physical support, serving as a critical mediator in cancer-cell evolution, immune modulation, and treatment outcomes. Innovations targeting the TME, including strategies focused on the vasculature, immune checkpoints, and T-cell therapies, have forged new pathways for clinical intervention. However, the heterogeneity and complexity of the TME present significant challenges, necessitating deeper exploration of its components and their interplay to enhance therapeutic efficacy. This review underscores the imperative for integrated research strategies that amalgamate insights from tumor biology, immunology, and systems biology. Such an approach aims to refine cancer treatments and improve patient prognoses by exploiting the TME’s complexity.

Yoo HC, Han JM. Amino acid metabolism in cancer drug resistance. Cells. 2022;11(1):140. https://doi.org/10.3390/cells11010140. (Published 2022 Jan 2).CrossRefPubMedPubMedCentral

Sun Y, Wang R, Qiao M, Xu Y, Guan W, Wang L. Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. J Cell Physiol. 2018;233(9):6359–69. https://doi.org/10.1002/jcp.26433.CrossRefPubMed

Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205–15. https://doi.org/10.1016/j.canlet.2015.07.044.CrossRefPubMed

Silva VL, Al-Jamal WT. Exploiting the cancer niche: tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. J Control Release. 2017;253:82–96. https://doi.org/10.1016/j.jconrel.2017.03.013.CrossRefPubMed

Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P. Combinatorial therapy in tumor microenvironment: where do we stand? Biochim Biophys Acta Rev Cancer. 2021;1876(2): 188585. https://doi.org/10.1016/j.bbcan.2021.188585.CrossRefPubMed

Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45. https://doi.org/10.1186/s12916-015-0278-7. (Published 2015 Mar 5).CrossRefPubMedPubMedCentral

Zhou H, Wang M, Zhang Y, Su Q, Xie Z, Chen X, et al. Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis. Cancer Commun (Lond). 2022;42(5):374–400. https://doi.org/10.1002/cac2.12294.CrossRefPubMed

Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH. Quantitative analyses of the tumor microenvironment composition and orientation in the era of precision medicine. Front Oncol. 2018;8:390. https://doi.org/10.3389/fonc.2018.00390. (Published 2018 Sep 25).CrossRefPubMedPubMedCentral

Ma K, Zhang L. Overview: lipid metabolism in the tumor microenvironment. Adv Exp Med Biol. 2021;1316:41–7. https://doi.org/10.1007/978-981-33-6785-2_3.CrossRefPubMed

10.

Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–5. https://doi.org/10.1016/j.cub.2020.06.081.CrossRefPubMedPubMedCentral

11.

Abadjian MZ, Edwards WB, Anderson CJ. Imaging the tumor microenvironment. Adv Exp Med Biol. 2017;1036:229–57. https://doi.org/10.1007/978-3-319-67577-0_15.CrossRefPubMed

12.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101(5):531–40. https://doi.org/10.3324/haematol.2015.139493.CrossRefPubMedPubMedCentral

13.

Kao KC, Vilbois S, Tsai CH, Ho PC. Metabolic communication in the tumour-immune microenvironment. Nat Cell Biol. 2022;24(11):1574–83. https://doi.org/10.1038/s41556-022-01002-x.CrossRefPubMed

14.

Farc O, Cristea V. An overview of the tumor microenvironment, from cells to complex networks (review). Exp Ther Med. 2021;21(1):96. https://doi.org/10.3892/etm.2020.9528.CrossRefPubMed

15.

Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364. https://doi.org/10.3389/fimmu.2021.656364. (Published 2021 May 27).CrossRefPubMedPubMedCentral

16.

Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018;18(6):359–76. https://doi.org/10.1038/s41568-018-0006-7.CrossRefPubMed

17.

Suwa T, Kobayashi M, Nam JM, Harada H. Tumor microenvironment and radioresistance. Exp Mol Med. 2021;53(6):1029–35. https://doi.org/10.1038/s12276-021-00640-9.CrossRefPubMedPubMedCentral

18.

Cheng YQ, Wang SB, Liu JH, Jin L, Liu Y, Li CY, et al. Modifying the tumour microenvironment and reverting tumour cells: new strategies for treating malignant tumours. Cell Prolif. 2020;53(8): e12865. https://doi.org/10.1111/cpr.12865.CrossRefPubMedPubMedCentral

19.

Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933–59. https://doi.org/10.1158/2159-8290.CD-20-1808.CrossRefPubMed

20.

Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–14. https://doi.org/10.1016/j.trecan.2022.07.002.CrossRefPubMed

21.

Yuan Y, Li H, Pu W, Chen L, Guo D, Jiang H, et al. Cancer metabolism and tumor microenvironment: fostering each other? Sci China Life Sci. 2022;65(2):236–79. https://doi.org/10.1007/s11427-021-1999-2.CrossRefPubMed

22.

Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 2023;29(6):1009–16. https://doi.org/10.1158/1078-0432.CCR-22-1031.CrossRefPubMed

23.

Schulz M, Salamero-Boix A, Niesel K, Alekseeva T, Sevenich L. Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis. Front Immunol. 2019;10:1713. https://doi.org/10.3389/fimmu.2019.01713. (Published 2019 Jul 24.).CrossRefPubMedPubMedCentral

24.

Yin Z, Bai L, Li W, Zeng T, Tian H, Cui J. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. J Exp Clin Cancer Res. 2019;38(1):403. https://doi.org/10.1186/s13046-019-1409-3. (Published 2019 Sep 13).CrossRefPubMedPubMedCentral

25.

Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526–36. https://doi.org/10.1038/s41568-021-00366-w.CrossRefPubMedPubMedCentral

26.

Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016–30. https://doi.org/10.7150/thno.51777. (Published 2021 Jan 1).CrossRefPubMedPubMedCentral

27.

de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403. https://doi.org/10.1016/j.ccell.2023.02.016.CrossRefPubMed

28.

Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36–50. https://doi.org/10.1016/j.cmet.2019.06.001.CrossRefPubMed

29.

Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40:169–93. https://doi.org/10.1146/annurev-immunol-101220-015603.CrossRefPubMed

30.

Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11(5):1067–81. https://doi.org/10.1158/2159-8290.CD-20-1211.CrossRefPubMedPubMedCentral

31.

Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci. 2022;29(1):83. https://doi.org/10.1186/s12929-022-00866-3. (Published 2022 Oct 17).CrossRefPubMedPubMedCentral

32.

Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66. https://doi.org/10.1158/0008-5472.CAN-18-3962.CrossRefPubMedPubMedCentral

33.

Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221: 107753. https://doi.org/10.1016/j.pharmthera.2020.107753.CrossRefPubMed

34.

Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18(7):3019–33. https://doi.org/10.7150/ijbs.72534. (Published 2022 Apr 24).CrossRefPubMedPubMedCentral

35.

Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421–33. https://doi.org/10.1016/j.ccell.2023.01.009.CrossRefPubMedPubMedCentral

36.

Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59: 100796. https://doi.org/10.1016/j.drup.2021.100796.CrossRefPubMedPubMedCentral

37.

Liu Q, Luo Q, Ju Y, Song G. Role of the mechanical microenvironment in cancer development and progression. Cancer Biol Med. 2020;17(2):282–92. https://doi.org/10.20892/j.issn.2095-3941.2019.0437.CrossRefPubMedPubMedCentral

38.

Thakkar S, Sharma D, Kalia K, Tekade RK. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater. 2020;101:43–68. https://doi.org/10.1016/j.actbio.2019.09.009.CrossRefPubMed

39.

Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013;59(1):85–93. https://doi.org/10.1373/clinchem.2012.185363.CrossRefPubMed

40.

Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25(24):2559–72. https://doi.org/10.1101/gad.169029.111.CrossRefPubMedPubMedCentral

41.

Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24(1):28–50. https://doi.org/10.1038/s41568-023-00635-w.CrossRefPubMed

42.

Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859–74. https://doi.org/10.1016/j.immuni.2021.01.012.CrossRefPubMedPubMedCentral

43.

Wong-Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2021;12(5):426–35. https://doi.org/10.1007/s13238-020-00813-8.CrossRefPubMed

44.

Yang Q, Wang B, Zheng Q, Li H, Meng X, Zhou F, et al. A review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Adv Sci (Weinh). 2023;10(15): e2207366. https://doi.org/10.1002/advs.202207366.CrossRefPubMed

45.

Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371(6536):eabc4552. https://doi.org/10.1126/science.abc4552.CrossRefPubMedPubMedCentral

46.

Xie Y, Xie F, Zhou X, Zhang L, Yang B, Huang J, et al. Microbiota in tumors: from understanding to application. Adv Sci (Weinh). 2022;9(21): e2200470. https://doi.org/10.1002/advs.202200470.CrossRefPubMed

47.

El Tekle G, Garrett WS. Bacteria in cancer initiation, promotion and progression. Nat Rev Cancer. 2023;23(9):600–18. https://doi.org/10.1038/s41568-023-00594-2.CrossRefPubMed

48.

Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8(1):35. https://doi.org/10.1038/s41392-022-01304-4. (Published 2023 Jan 16).CrossRefPubMedPubMedCentral

49.

Fu A, Yao B, Dong T, Cai S. Emerging roles of intratumor microbiota in cancer metastasis. Trends Cell Biol. 2023;33(7):583–93. https://doi.org/10.1016/j.tcb.2022.11.007.CrossRefPubMed

50.

Ferrari V, Rescigno M. The intratumoral microbiota: friend or foe? Trends Cancer. 2023;9(6):472–9. https://doi.org/10.1016/j.trecan.2023.03.005.CrossRefPubMed

51.

Wu J, Zhang P, Mei W, Zeng C. Intratumoral microbiota: implications for cancer onset, progression, and therapy. Front Immunol. 2024;14:1301506. https://doi.org/10.3389/fimmu.2023.1301506. (Published 2024 Jan 16).CrossRefPubMedPubMedCentral

52.

Yang J, Wang Q, Wang C, Yang R, Ahmed M, Kumaran S, et al. Pseudomonas aeruginosa synthesized silver nanoparticles inhibit cell proliferation and induce ROS mediated apoptosis in thyroid cancer cell line (TPC1). Artif Cells Nanomed Biotechnol. 2020;48(1):800–9. https://doi.org/10.1080/21691401.2019.1687495.CrossRefPubMed

53.

Cui J, Chen Y, Wang HY, Wang RF. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 2014;10(11):3270–85. https://doi.org/10.4161/21645515.2014.979640.CrossRefPubMed

54.

Saba E, Farhat M, Daoud A, Khashan A, Forkush E, Menahem NH, et al. Oral bacteria accelerate pancreatic cancer development in mice. Gut. 2024;73(5):770–86. https://doi.org/10.1136/gutjnl-2023-330941. (Published 2024 Apr 5).CrossRefPubMed

55.

Liu W, Zhang X, Xu H, Li S, Lau HC, Chen Q, et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterology. 2021;160(7):2395–408. https://doi.org/10.1053/j.gastro.2021.02.020.CrossRefPubMed

56.

Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018;198(9):1188–98. https://doi.org/10.1164/rccm.201710-2118OC.CrossRefPubMedPubMedCentral

57.

Rezania S, Amirmozaffari N, Rashidi N, et al. The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int. 2014;14:54. https://doi.org/10.1186/1475-2867-14-54. (Published 2014 Jun 19).CrossRefPubMedPubMedCentral

58.

Kong C, Yan X, Zhu Y, Zhu H, Luo Y, Liu P, et al. Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome P450/epoxyoctadecenoic acid axis via TLR4/Keap1/NRF2 signaling. Cancer Res. 2021;81(17):4485–98. https://doi.org/10.1158/0008-5472.CAN-21-0453.CrossRefPubMed

59.

Kong X, Zhang Y, Xiang L, You Y, Duan Y, Zhao Y, et al. Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression. J Exp Clin Cancer Res. 2023;42(1):236. https://doi.org/10.1186/s13046-023-02817-8. (Published 2023 Sep 9).CrossRefPubMedPubMedCentral

60.

Chen Y, Peng Y, Yu J, Chen T, Wu Y, Shi L, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8(19):31802–14. https://doi.org/10.18632/oncotarget.15992.CrossRefPubMedPubMedCentral

61.

Li S, Liu J, Zheng X, Ren L, Yang Y, Li W, et al. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biol Med. 2021. https://doi.org/10.20892/j.issn.2095-3941.2020.0651. (Published online September 30, 2021).CrossRefPubMedPubMedCentral

62.

van Senten JR, Fan TS, Siderius M, Smit MJ. Viral G protein-coupled receptors as modulators of cancer hallmarks. Pharmacol Res. 2020;156: 104804. https://doi.org/10.1016/j.phrs.2020.104804.CrossRefPubMed

63.

Mortara L, Benest AV, Derosa L, Chouaib S, Ribatti D. Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: the angiogenic switch in the tumor microenvironment as a key target for immunotherapies. Front Immunol. 2022;13:1045074. https://doi.org/10.3389/fimmu.2022.1045074. (Published 2022 Oct 6).CrossRefPubMedPubMedCentral

64.

Laplane L, Duluc D, Bikfalvi A, Larmonier N, Pradeu T. Beyond the tumour microenvironment [published correction appears in Int J Cancer. 2021 Mar 15;148(6):E5. 10.1002/ijc.33412]. Int J Cancer. 2019;145(10):2611–8. https://doi.org/10.1002/ijc.32343.CrossRefPubMedPubMedCentral

65.

Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. https://doi.org/10.1080/19490976.2021.1980347.CrossRefPubMedPubMedCentral

66.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight. 2018;3(4):e94952. https://doi.org/10.1172/jci.insight.94952. (Published 2018 Feb 22).CrossRefPubMedPubMedCentral

67.

Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gómez L, Verginadis I, Bittinger K, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Investig. 2020;130(1):466–79. https://doi.org/10.1172/JCI124332.CrossRefPubMed

68.

Wang Y, Han Y, Yang C, Bai T, Zhang C, Wang Z, et al. Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment. Nat Commun. 2024;15(1):4194. https://doi.org/10.1038/s41467-024-48662-x. (Published 2024 May 17).CrossRefPubMedPubMedCentral

69.

Ma J, Huang L, Hu D, Zeng S, Han Y, Shen H. The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor? J Exp Clin Cancer Res. 2021;40(1):327. https://doi.org/10.1186/s13046-021-02128-w. (Published 2021 Oct 16).CrossRefPubMedPubMedCentral

70.

Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40(2):153-167.e11. https://doi.org/10.1016/j.ccell.2022.01.003.CrossRefPubMedPubMedCentral

71.

Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. https://doi.org/10.1038/s41392-020-0134-x. (Published 2020 Mar 12).CrossRefPubMedPubMedCentral

72.

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92. https://doi.org/10.1093/annonc/mdw168.CrossRefPubMed

73.

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204. https://doi.org/10.1186/s13046-020-01709-5. (Published 2020 Sep 30).CrossRefPubMedPubMedCentral

74.

Siddhartha R, Garg M. Interplay between extracellular matrix remodeling and angiogenesis in tumor ecosystem. Mol Cancer Ther. 2023;22(3):291–305. https://doi.org/10.1158/1535-7163.MCT-22-0595.CrossRefPubMed

75.

Lambert AW, Zhang Y, Weinberg RA. Cell-intrinsic and microenvironmental determinants of metastatic colonization [published correction appears in Nat Cell Biol. 2024 Jul;26(7):1225. 10.1038/s41556-024-01458-z]. Nat Cell Biol. 2024;26(5):687–97. https://doi.org/10.1038/s41556-024-01409-8.CrossRefPubMed

76.

Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. https://doi.org/10.1186/s12943-023-01860-5. (Published 2023 Oct 2).CrossRefPubMedPubMedCentral

Title: Tumor microenvironment as a complex milieu driving cancer progression: a mini review
Authors: Zhengrui Li
Jing Li
Xiaolei Bai
Xufeng Huang
Qi Wang
Publication date: 28-09-2024
Publisher: Springer International Publishing
Keywords: Respiratory Microbiota
Metastasis
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03697-w

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

12-12-2024
Lymphoma
News

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

12-12-2024
Mantle Cell Lymphoma
News

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

12-12-2024
Lymphoma
News

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Abstract

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma